

The Impact of Drug Formulation on Bioavailability: Key Considerations

Tejvir Kaur

Department of Pharmacy
Pharmaceutical Sciences,
Government Medical College,
Patiala, Punjab.

Correspondence:

Dr. Tejvir Kaur,
Department of Pharmacy
Pharmaceutical
Sciences(Pharmaceutics),
Government Medical College,
Patiala, Punjab.
E-mail: tejkaur07@gmail.com

How to cite this article: Kaur T.
The Impact of Drug Formulation on
Bioavailability: Key Considerations
Innov Pharm Planet (IP-Planet)
2016;04(4):12-15.

Source of Support: Nil.

Conflicts of Interest: None declared.

Date of Submission: 16-10-2016

Date of Revision: 24-11-2016

Date of Acceptance: 13-11-2016

ABSTRACT:

The bioavailability of a drug is a critical determinant of its therapeutic efficacy, directly influencing the drug's absorption, distribution, metabolism, and elimination. Drug formulation plays a pivotal role in determining bioavailability, with various factors influencing the extent and rate at which the active pharmaceutical ingredient (API) reaches systemic circulation. This review explores the key considerations regarding how drug formulations impact bioavailability. We examine the fundamental factors such as drug solubility, particle size, and dissolution rate, as well as the role of excipients in formulation design. Advanced strategies to enhance bioavailability, including nanoparticle-based formulations, prodrugs, and controlled release systems, are discussed in detail. Additionally, the review highlights pharmacokinetic factors, such as absorption, first-pass metabolism, and distribution, that are influenced by the formulation. Challenges such as patient variability, formulation stability, and regulatory issues are also addressed. Recent advances in formulation technologies, including biopharmaceutical classification systems and personalized medicine approaches, are presented to illustrate ongoing efforts to improve bioavailability. Overall, this review provides comprehensive insights into the complex relationship between drug formulation and bioavailability, emphasizing the importance of formulation strategies in optimizing drug therapy and enhancing patient outcomes.

KEYWORDS: Bioavailability, drug formulation, solubility, nanoparticles, controlled release.

INTRODUCTION

Drug formulation plays a crucial role in determining the bioavailability of pharmaceutical drugs. Bioavailability refers to the fraction of an administered drug that reaches the systemic circulation and produces a pharmacological effect. Formulation strategies can significantly influence drug bioavailability by affecting factors such as solubility, dissolution rate, permeability, and metabolism. Formulation strategies can enhance drug solubility through techniques like particle size reduction, complexation, and solid dispersion. These methods improve the dissolution rate and permeability of drugs, leading to increased bioavailability. For example, complexation involves forming inclusion complexes with cyclodextrins or other excipients to enhance the solubility and stability of poorly soluble drugs. Additionally, permeation enhancers and prodrug approaches can enhance drug absorption across biological membranes¹. Formulation strategies also impact drug stability by protecting drugs from degradation pathways such as hydrolysis, oxidation, and photolysis. Techniques like microencapsulation

and lyophilization provide physical protection and minimize exposure to environmental factors, which is particularly useful for

sensitive drugs like proteins and peptides. Controlled-release formulations, such as matrix tablets or osmotic pumps, can provide sustained drug release, minimizing fluctuations in plasma concentration and improving bioavailability. Differences in bioavailability among formulations of a given drug can have clinical significance. Knowing whether drug formulations are bioequivalent is essential, as bioequivalence ensures that drug products result in equivalent tissues.

For drugs with a narrow therapeutic index, differences in bioavailability may lead to substantial therapeutic non-equivalence, affecting efficacy and safety. Therefore, understanding and optimizing drug formulation is critical for ensuring effective and safe treatment outcomes².

FUNDAMENTALS OF BIOAVAILABILITY

Bioavailability is defined as the fraction of an administered dose of a drug that reaches the systemic circulation in its active form, enabling

Access this article online

Website: <https://innovationaljournals.com/index.php/ip>

e-ISSN: 2348-7275

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution Non-commercial Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

of bioavailability varies significantly across different routes of administration:

Intravenous (IV) Administration:

Bioavailability is 100% because the drug is directly introduced into the bloodstream, bypassing absorption barriers.

Oral Administration: Bioavailability is typically lower due to factors like first-pass metabolism and intestinal absorption variability.

Other Routes: Bioavailability can vary widely depending on the route, such as topical, parenteral, or rectal administration, each with its own absorption characteristics³.

Factors Affecting Bioavailability

Several factors influence drug bioavailability:

Drug Solubility: Affects how easily a drug dissolves in bodily fluids, impacting absorption.

Permeability: The ability of a drug to cross biological membranes, such as the intestinal epithelium.

Metabolism: Enzymatic processes that can degrade drugs before they reach systemic circulation, notably first-pass metabolism in the liver.

First-Pass Effect: Drugs absorbed orally must pass through the liver before reaching systemic circulation, where they may be metabolized, reducing bioavailability⁴.

Measurement of Bioavailability

Bioavailability is typically measured through pharmacokinetic studies, focusing on parameters such as:

Area Under the Curve (AUC): The total exposure of the body to the drug, calculated from plasma concentration over time.

Pharmacokinetic Studies: Involving both in vitro and in vivo experiments to assess drug absorption, distribution, metabolism, and excretion (ADME). These studies help determine the extent and rate at which a drug reaches systemic circulation⁵.

KEY FORMULATION FACTORS AFFECTING BIOAVAILABILITY**Drug Solubility and Dissolution Rate**

Drug solubility and dissolution rate are critical factors influencing bioavailability. Solubility determines how easily a drug dissolves in bodily fluids, while the dissolution rate affects how quickly this process occurs. Drugs with high solubility and rapid dissolution rates are generally more bioavailable because they can be absorbed more efficiently. Conversely, poorly soluble drugs may require formulation strategies like complexation or solubilization to enhance their solubility and dissolution rates, thereby improving absorption and bioavailability.

Particle Size and Surface Area

Altering particle size, particularly through nanotechnology, can significantly impact dissolution and absorption. Smaller particles have a larger surface area relative to their volume, which enhances their dissolution rate in biological fluids. This increased surface area facilitates faster absorption, leading to improved bioavailability. Techniques like micronization and nanonization are used to reduce particle size, making drugs more bioavailable.

Formulation Excipients

Excipients play a crucial role in drug formulation by affecting drug release and bioavailability. Common excipients include:

Binders and Fillers: These help maintain the physical structure of tablets or capsules but can sometimes impede drug release if not properly optimized.

Surfactants: Nonionic surfactants like polysorbates can enhance drug solubility and permeability, thereby increasing bioavailability. They act as wetting agents, improving the interaction between the drug and biological fluids.

Complexing Agents: These can form complexes with drugs to alter their solubility, stability, or permeability. While beneficial in some cases, complexation can also reduce bioavailability if the complex does not dissociate properly at the absorption site.

Dosage Form and Delivery System

Different dosage forms significantly affect drug bioavailability:

Liquid Formulations (Solutions and Suspensions): Generally, offer higher bioavailability compared to solid forms because they eliminate the need for dissolution in the gastrointestinal tract. Solutions are particularly effective for rapid absorption, while suspensions are useful for poorly soluble drugs.

Capsules and Tablets: These solid forms require dissolution before absorption, which can be slower than liquid formulations. Coated tablets, especially enteric-coated ones, may further delay absorption by protecting the drug from stomach acid but releasing it in the intestines.

Other Forms: Emulsions and sustained-release formulations can also impact bioavailability by controlling the rate of drug release. Emulsions facilitate absorption by presenting drugs in a more soluble form, while sustained-release systems maintain drug levels over a longer period⁶.

ADVANCED FORMULATION TECHNIQUES TO ENHANCE BIOAVAILABILITY

Nanoparticle-Based Formulations

Nanoparticle-based formulations, including nanoparticles, micelles, and liposomes, have emerged as powerful tools to enhance drug solubility and absorption. These systems can encapsulate both hydrophilic and lipophilic drugs, improving their solubility and facilitating their transport across biological barriers. For instance, nanoparticles can be engineered to target specific tissues or cells, increasing drug concentration at the site of action while minimizing systemic exposure. Micelles, formed from amphiphilic molecules, can solubilize poorly soluble drugs, enhancing their absorption. Liposomes, composed of phospholipid bilayers, can encapsulate drugs and protect them from degradation, improving bioavailability by facilitating controlled release and targeted delivery.

Solid Lipid Nanoparticles (SLNs) and Lipid-Core Micelles

Solid Lipid Nanoparticles (SLNs) and lipid-core micelles are lipid-based systems that significantly enhance bioavailability. SLNs are composed of a solid lipid core that can encapsulate drugs, protecting them from degradation and improving their solubility and absorption. They can be absorbed through the intestinal epithelium via endocytosis, enhancing the bioavailability of poorly soluble drugs. The use of SLNs has been successful in

improving the bioavailability of drugs like irbesartan and curcumin by stabilizing them and facilitating their absorption. Lipid-core micelles, formed during the digestion of SLNs, can further solubilize drugs, enhancing their absorption through the intestinal epithelium.

Prodrug Strategies

Prodrug strategies involve converting a pharmacologically active drug into a derivative that requires metabolic conversion to release the active drug. This approach can increase bioavailability by improving drug solubility or targeting specific sites. Prodrugs can be designed to enhance solubility, reduce first-pass metabolism, or target specific tissues, thereby improving drug delivery and efficacy. For example, prodrugs can be activated by specific enzymes found in target tissues, ensuring that the active drug is released only where needed, which can enhance therapeutic effects while minimizing side effects.

Controlled Release Systems

Controlled release systems, including sustained and delayed release formulations, have a significant impact on bioavailability. These systems are designed to maintain drug concentrations within a therapeutic window over an extended period, reducing the need for frequent dosing and improving patient compliance. Sustained release formulations ensure a steady drug release, maintaining consistent plasma levels and enhancing bioavailability by minimizing peak-to-trough fluctuations⁷. Delayed release formulations, such as enteric-coated tablets, protect drugs from degradation in the stomach and release them in the intestines, where they can be absorbed more effectively. This approach can improve the bioavailability of drugs that are sensitive to acidic environments or have limited solubility in the stomach.

CONCLUSION

In conclusion, drug formulation significantly influences bioavailability, affecting the efficacy and therapeutic outcomes of pharmaceutical products. By optimizing factors such as solubility, particle size, and release mechanisms, formulations can enhance drug absorption and minimize metabolic challenges. Advances in formulation technologies, including nanotechnology and prodrug strategies, hold great promise for improving bioavailability. Continued research and

innovation in this field are essential for developing more effective and personalized drug therapies.

REFERENCE

1. Panakanti, R., & Narang, A. S. (2012). Impact of excipient interactions on drug bioavailability from solid dosage forms. *Pharmaceutical research*, 29, 2639-2659.
2. Beg, S., Swain, S., Rizwan, M., Irfanuddin, M., & Shobha Malini, D. (2011). Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. *Current Drug Delivery*, 8(6), 691-702.
3. Riding, M. J., Doick, K. J., Martin, F. L., Jones, K. C., & Semple, K. T. (2013). Chemical measures of bioavailability/bioaccessibility of PAHs in soil: fundamentals to application. *Journal of hazardous materials*, 261, 687-700.
4. Russell, R. M. (2001). Factors in aging that effect the bioavailability of nutrients. *The Journal of nutrition*, 131(4), 1359S-1361S.
5. Harmsen, J. (2007). Measuring bioavailability: from a scientific approach to standard methods. *Journal of Environmental quality*, 36(5), 1420-1428.
6. Pathak, K., & Raghuvanshi, S. (2015). Oral bioavailability: issues and solutions via nanoformulations. *Clinical pharmacokinetics*, 54, 325-357.
7. Kumar, S., Dilbaghi, N., Rani, R., Bhanjana, G., & Umar, A. (2013). Novel approaches for enhancement of drug bioavailability. *Rev Adv Sci Eng*, 2(2), 133-154.